Study explorer (study characteristics and results) method abbreviations

display ongoing studies
Study studied treatmentcontrol treatmentpatientsrisk of biassample sizes Results

COVID 19 hospitalized meta-analysis

Nojomi, 2020
 
IRCT20180725040596N2
RCTlopinavir/ritonavirumifenovir (arbidol)COVID 19 hospitalizedsome concern
50/50 inconclusive
    no demonstrated benefit a
RECOVERY, 2020
 
NCT04381936
RCTlopinavir/ritonavirstandard of careCOVID 19 hospitalizedsome concern
1616/3424 inconclusive
  • inconclusive 3 % increase in deaths (PE) with a moderate degree of certainty due to some concern in risk of bias
the trial Steering Committee concluded that there is no beneficial effect of lopinavir-ritonavir in patients hospitalised with COVID-19 and closed randomisation to that treatment arm
SOLIDARITY (lopi/rito), 2020
 
NCT04315948
RCTlopinavir/ritonavirstandard of careCOVID 19 hospitalizedsome concern
1399/1372 inconclusive
  • inconclusive 0 % increase in deaths (PE) with a moderate degree of certainty due to some concern in risk of bias

COVID-19 mild to moderate meta-analysis

ELACOI (lopinavir/ritonavir), 2020
 
NCT04252885
RCTlopinavir/ritonavirstandard of careCOVID-19 mild to moderatesome concern
21/7 inconclusive
    no demonstrated benefit a

COVID-19 severe or critically meta-analysis

Cao B, 2020
 
ChiCTR2000029308
RCTlopinavir/ritonavirstandard of careCOVID-19 severe or criticallysome concern
99/100 suggested
    no demonstrated benefit a
  • inconclusive 31 % increase in clinical improvement,clinical improvement (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
  • suggested 94 % increase in clinical improvement (14-day) with a moderate degree of certainty due to some concern in risk of bias

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);